[go: up one dir, main page]

AR094411A1 - Carboxamidas basadas en pirazolilo ii - Google Patents

Carboxamidas basadas en pirazolilo ii

Info

Publication number
AR094411A1
AR094411A1 ARP140100091A ARP140100091A AR094411A1 AR 094411 A1 AR094411 A1 AR 094411A1 AR P140100091 A ARP140100091 A AR P140100091A AR P140100091 A ARP140100091 A AR P140100091A AR 094411 A1 AR094411 A1 AR 094411A1
Authority
AR
Argentina
Prior art keywords
residue
independently
polysubstituted
monosubstituted
represent
Prior art date
Application number
ARP140100091A
Other languages
English (en)
Inventor
Dr Nordhoff Sonja
Dr Wachten Sebastian
Dr Kless Achim
Dr Voss Felix
Dr Ritter Stefanie
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of AR094411A1 publication Critical patent/AR094411A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se relaciona con compuestos de carboxamidas basadas en pirazolilo que son útiles como inhibidores de ICRAC, con composiciones farmacéuticas que contienen a estos compuestos y con estos compuestos para su uso en el tratamiento y/o la profilaxis de enfermedades y/o trastornos, en particular enfermedades inflamatorias y/o trastornos de tipo inmune. Reivindicación 1: Un compuesto caracterizado porque es de fórmula general (1), donde R¹ denota residuo alifático C₁₋₄, no sustituido o monosustituido o polisustituido; o residuo cicloalifático C₃₋₆ o un residuo heterocicloalifático de entre 3 y 7 miembros, en cada caso no sustituido o monosustituido o polisustituido y en cada caso opcionalmente conectado a través de un grupo alifático C₁₋₄, que a su vez puede no estar sustituido o estar monosustituido o polisustituido; con la condición de que si R¹ representa un residuo heterocicloalifático de entre 3 y 7 miembros, dicho residuo heterocicloalifático de entre 3 y 7 miembros se conecta a la parte restante de la estructura de acuerdo con la fórmula general (1) a través de un átomo de carbono del residuo heterocicloalifático de entre 3 y 7 miembros; R² denota H; F; Cl; Br; I; NO₂; CN; CF₃; CF₂H; CFH₂; R¹³; OH; O-R¹³; NH₂; N(H)R¹³; N(R¹³)₂; U representa C-R⁴ o N o N⁺-O⁻, V representa C-R⁵ o N o N⁺-O⁻, W representa C-R⁶ o N o N⁺-O⁻, y X representa C-R⁷ o N⁺-O⁻, con la condición de que 0, 1, 2 ó 3 de las variables T, U, y, W y X en forma independiente entre sí representan N o N⁺-O⁻, donde 0 ó 1 de las variables T, U, y, W y X en forma independiente entre sí representan N⁺-O⁻ y con la condición de que al menos uno de U, V y W no representa N, donde R⁴, R⁵ y R⁶ se seleccionan en forma independiente entre sí entre el grupo que consiste en H; F; Cl; Br; I; NO₂ CN; CF₃; CF₂H; CFH₂; CF₂Cl; CFCl₂; residuo alifático C₁₋₈, no sustituido o monosustituido o polisustituido; C(=O)OH; C(=O)-R¹³; C(=O)R¹⁴; C(=O)-OR¹³; C(=O)-OR¹⁴; C(=O)-N(H)(OH); C(=N-OH)-H; C(=N-OH)-R¹³; C(=N-OH)-R¹⁴; C(=N-O-R¹³)-H; C(=N-O-R¹³)-R¹³; C(=N-O-R¹³)-R¹⁴; C(=O)NH₂; C(=O)-N(H)R¹³; C(=O)-N(R¹³)₂; C(=O)N(H)R¹⁴; C(=O)-N(R¹⁴)₂; C(=O)-N(R¹³)(R¹⁴); C(=O)-N(Rᵃ)(Rᵇ); OH; OR¹³; OCF₃; OCF₂H; OCFH₂; OCF₂Cl; OCFCl₂; OR¹⁴; O-C(=O)R¹³; O-C(=O)R¹⁴; O-C(=O)-N(H)R¹³; O-C(=O)-N(H)R¹⁴; O-C(=O)-N(R¹³)₂; O-C(=O)-N(R¹⁴)₂; O-C(=O)-N(R¹³)(R¹⁴); O-C(=O)-N(Rᵃ)(Rᵇ); NH₂; N(H)R¹³; N(R¹³)₂; N(H)R¹⁴N(R¹⁴)₂; N(R¹³)(R¹⁴); N(Rᵃ)(Rᵇ); NH-C(=O)-R¹⁴; NH-C(=O)-R¹³; N(R¹³)-C(=O)-R¹³; N(R¹³)-C(=O)-R¹⁴; NH-S(=O)₂-R¹³; N(R¹³)-S(=O)₂-R¹³; NH-S(=O)₂-R¹⁴; N(R¹³)-S(=O)₂-R¹⁴; N(H)-C(=O)-OR¹³; N(H)-C(O)-OR¹⁴; N(R¹³)-C(=O)-OR¹³; N(R¹³)-C(O)-OR¹⁴; N(H)-C(=O)-NH₂; N(H)C(=O)-N(H)R¹³; N(H)-C(=O)-N(H)R¹⁴; N(H)-C(=O)-N(R¹³)₂; N(H)-C(=O)-N(R¹⁴)₂; N(H)-C(=O)-N(R¹³)(R¹⁴); N(H)-C(=O)N(Rᵃ)(Rᵇ); N(R¹³)-C(=O)-NH₂; N(R¹³)-C(=O)-N(H)R¹³; N(R¹³)-C(O)-N(H)R¹⁴; N(R¹³)-C(=O)-N(R¹³)₂; N(R¹³)-C(=O)-N(R¹⁴)₂; N(R¹³)-C(=O)-N(R¹³)(R¹⁴); N(R¹³)-C(=O)-N(Rᵃ)(Rᵇ); SH; S-R¹³; SCF₃; S-R¹⁴; S(O)₂OH; S(O)₂-R¹³; S(=O)₂-R¹⁴; S(=O)-R¹³; S(=O)-R¹⁴; S(=O)₂-OR¹³; S(=O)₂-OR¹⁴; S(=O)₂-N(H)(R¹³); S(=O)₂-N(R¹³)₂; S(=O)₂-N(H)(R¹⁴); S(=O)₂-N(R¹³)(R¹⁴); S(=O)₂-N(Rᵃ)(Rᵇ); y R³ y R⁷ se seleccionan en forma independiente entre sí entre el grupo que consiste en H; F; CI; Br; I; NO₂; CN; CF₃; CF₂H; CFH₂; CF₂Cl; CFCl₂; R¹³; R¹⁴; C(=O)OH; C(=O)-R¹³; C(=O)R¹⁴; C(=O)-OR¹³; C(=O)-OR¹⁴; C(=O)-N(H)(OH); C(=N-OH)-H; C(=N-OH)-R¹³; C(=N-OH)-R¹⁴; C(=N-O-R¹³)-H; C(=N-O-R¹³)-R¹³; C(=N-O-R¹³)-R¹⁴; C(=O)NH₂; C(=O)-N(H)R¹³; C(=O)-N(R¹³)₂; C(=O)-N(H)R¹⁴; C(=O)-N(R¹⁴)₂; C(=O)-N(R¹³)(R¹⁴); C(=O)-N(Rᵃ)(Rᵇ); OH; OR¹³; OCF₃; OCF₂H; OCFH₂ OCF₂Cl; OCFCl₂; OR¹⁴; O-C(=O)R¹³; O-C(=O)R¹⁴; O-C(=O)-N(H)R¹³; O-C(=O)-N(H)R¹⁴; O-C(=O)-N(R¹³)₂; O-C(O)-N(R¹⁴)₂; O-C(O)-N(R¹³)(R¹⁴); O-C(=O)-N(Rᵃ)(Rᵇ); NH₂; N(H)R¹³; N(R¹³)₂; N(H)R¹⁴; N(R¹⁴)₂; N(R¹³)(R¹⁴); N(Rᵃ)(Rᵇ); NH-C(=O)-R¹⁴; NH-C(=O)R¹³; N(R¹³)-C(=O)-R¹³; N(R¹³)-C(=O)-R¹⁴; NH-S(=O)₂-R¹³; N(R¹³)-S(=O)₂-R¹³; NH-S(=O)₂-R¹⁴; N(R¹³)-S(=O)₂-R¹⁴; N(H)-C(=O)-OR¹³; N(H)-C(=O)-OR¹⁴; N(R¹³)-C(=O)-OR¹³; N(R¹³)-C(=O)-OR¹⁴; N(H)-C(=O)-NH₂; N(H)-C(=O)-N(H)R¹³; N(H)-C(=O)N(H)R¹⁴; N(H)-C(=O)-N(R¹³)₂; N(H)C(O)-N(R¹⁴)₂; N(H)-C(=O)-N(R¹³)(R¹⁴); N(H)-C(=O)-N(Rᵃ)(Rᵇ); N(R¹³)-C(=O)-NH₂; N(R¹³)C(O)-N(H)R¹³; N(R¹³)C(=O)-N(H)R¹⁴; N(R¹³)-C(=O)-N(R¹³)₂; N(R¹³)-C(=O)-N(R¹⁴)₂; N(R¹³)-C(=O)-N(R¹³)(R¹⁴); N(R¹³)-C(=O)-N(Rᵃ)(Rᵇ); SH; S-R¹³; SCF₃; SR¹⁴; S(=O)₂OH; S(=O)₂-R¹³; S(=O)₂-R¹⁴; S(=O)-R¹³; S(=O)R¹⁴; S(=O)₂-OR¹³; S(=O)₂-OR¹⁴; S(=O)₂-N(H)(R¹³); S(=O)₂-N(R¹³)₂; S(=O)₂-N(H)(R¹⁴); S(=O)₂-N(R¹³)(R¹⁴); S(=O)₂-N(Rᵃ)(Rᵇ); con la condición de que R³ no representa H; n representa 0 ó 1, donde, si n representa 1, luego K representa C-R⁹ o N o N⁺-O⁻, M representa C-R¹⁰ o N o N⁺-O⁻, Q representa C-R¹¹ o N o N⁺-O⁻, y R representa C-R¹² o N o N⁺-O⁻, con la condición de que 0, 1, 2 ó 3 de las variables K, M, Q y R en forma independiente entre sí representan N o N⁺-O⁻, donde 0 ó 1 de las variables K, M, Q y R en forma independiente representa N⁺-O⁻, donde, si n representa 0, entonces K representa C-R⁹ o N o N⁺-O⁻ ó O ó S o NH o N(residuo alifático C₁₋₄), M representa C-R¹⁰ o N o N⁺-O⁻ ó O ó S o NH o N(residuo alifático C₁₋₄) y Q representa C-R¹¹ o N o N⁺-O⁻ ó O ó S o NH o N(residuo alifático C₁₋₄), con la condición de que uno de K, M y Q representa O ó S o NH o N(residuo alifático C₁₋₄) y los restantes de K, M y Q en forma independiente representan C-R⁹, respectivamente C-R¹⁰, respectivamente C-R¹¹ o N o N⁺-O⁻ y con la condición de que 0, 1 ó 2 de las variables K, M y Q en forma independiente entre sí representan N o N⁺-O⁻, donde 0 ó 1 de las variables K, M y Q representa N⁺-O⁻, donde R⁸ se selecciona entre F, Cl, CF₃, CF₂H, CFH₂, CH₃, CN, OCF₂H, OCFH₂, y OCF₃, y donde R⁹, R¹⁰, R¹¹ y R¹² se seleccionan en forma independiente entre sí entre el grupo que consiste en H F; Cl; Br; I; NO₂; CN; CF₃ CF₂H; CFH₂ CF₂Cl; CFCl₂; R¹³; R¹⁴; C(=O)OH; C(=O)-R¹³; C(=O)R¹⁴; C(=O)-OR¹³; C(=O)-OR¹⁴; C(=O)-N(H)(OH); C(=N-OH)-H; C(=N-OH)-R¹³; C(=N-OH)-R¹⁴; C(=N-O-R¹³)-H; C(=N-O-R¹³)-R¹³; C(=N-O-R¹³)-R¹⁴; C(=O)NH₂; C(=O)-N(H)R¹³; C(=O)-N(R¹³)₂; C(=O)-N(H)R¹⁴; C(=O)-N(R¹⁴)₂; C(=O)-N(R¹³)(R¹⁴); C(=O)-N(Rᵃ)(Rᵇ); OH; OR¹³; OCF₃; OCF₂H; OCFH₂; OCF₂Cl; OCFCl₂; OR¹⁴; O-C(=O)R¹³; O-C(=O)R¹⁴; O-C(O)-N(H)R¹³; OC(O)-N(H)R¹⁴; O-C(=O)N(R¹³)₂; OC(=O)-N(R¹⁴)₂; O-C(=O)-N(R¹³)(R¹⁴); O-C(=O)N(Rᵃ)(Rᵇ); NH₂; N(H)R¹³; N(R¹³)₂; N(H)R¹⁴; N(R¹⁴)₂; N(R¹³)(R¹⁴); N(Rᵃ)(Rᵇ); NH-C(=O)-R¹⁴; NH-C(=O)-R¹³; N(R¹³)-C(=O)-R¹³; N(R¹³)-C(=O)-R¹⁴; NH-S(=O)₂-R¹³; N(R¹³)-S(=O)₂-R¹³; NH-S(=O)₂-R¹⁴; N(R¹³)-S(=O)₂-R¹⁴; N(H)-C(=O)OR¹³; N(H)-C(=O)-OR¹⁴; N(R¹³)-C(=O)-OR¹³; N(R¹³)-C(=O)-OR¹⁴; N(H)-C(O)-NH₂; N(H)C(O)-N(H)R¹³; N(H)-C(=O)N(H)R¹⁴; N(H)-C(=O)-N(R¹³)₂; N(H)-C(=O)-N(R¹⁴)₂; N(H)-C(=O)-N(R¹³)(R¹⁴); N(H)-C(=O)-N(Rᵃ)(Rᵇ); N(R¹³)-C(=O)-NH₂; N(R¹³)-C(=O)-N(H)R¹³; N(R¹³)-C(=O)-N(H)R¹⁴; N(R¹³)-C(=O)-N(R¹³)₂; N(R¹³)-C(=O)-N(R¹⁴)₂; N(R¹³)-C(=O)-N(R¹³)(R¹⁴); N(R¹³)-C(=O)-N(Rᵃ)(Rᵇ); SH; S-R¹³; SCF₃; SR¹⁴; S(=O)₂OH; S(=O)₂-R¹³; S(=O)₂-R¹⁴; S(=O)-R¹³; S(=O)R¹⁴; S(=O)₂-OR¹³; S(=O)₂-OR¹⁴; S(=O)₂-N(H)(R¹³); S(=O)₂-N(R¹³)₂; S(=O)₂-N(H)(R¹⁴); S(=O)₂-N(R¹³)(R¹⁴); S(=O)₂-N(Rᵃ)(Rᵇ); donde cada R¹³ en forma independiente en cada caso denota residuo alifático C₁₋₈, no sustituido o monosustituido o polisustituido; o residuo cicloalifático C₃₋₆ o residuo heterocicloalifático de entre 3 y 7 miembros, en cada caso no sustituido o monosustituido o polisustituido; o residuo cicloalifático C₃₋₆ o residuo heterocicloalifático de entre 3 y 7 miembros, en cada caso no sustituido o monosustituido o polisustituido, y en cada caso conectado a través de un residuo alifático C₁₋₄, no sus
ARP140100091A 2013-01-10 2014-01-10 Carboxamidas basadas en pirazolilo ii AR094411A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13000117 2013-01-10

Publications (1)

Publication Number Publication Date
AR094411A1 true AR094411A1 (es) 2015-07-29

Family

ID=47559266

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100091A AR094411A1 (es) 2013-01-10 2014-01-10 Carboxamidas basadas en pirazolilo ii

Country Status (15)

Country Link
US (1) US9078899B2 (es)
EP (1) EP2943197A1 (es)
JP (1) JP2016504397A (es)
KR (1) KR20150103752A (es)
CN (1) CN104884058A (es)
AR (1) AR094411A1 (es)
AU (1) AU2014204977A1 (es)
BR (1) BR112015016394A2 (es)
CA (1) CA2897560A1 (es)
EA (1) EA201500737A1 (es)
HK (1) HK1216301A1 (es)
IL (1) IL239789A0 (es)
MX (1) MX2015008912A (es)
WO (1) WO2014108336A1 (es)
ZA (1) ZA201505697B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015090579A1 (en) * 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides iv
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
JP2020527562A (ja) 2017-07-18 2020-09-10 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 置換３−ヘテロアリールオキシ−１ｈ−ピラゾール類及びそれらの塩、並びに、それらの除草活性物質としての使用
BR112021004893A2 (pt) 2018-09-14 2021-06-01 Rhizen Pharmaceuticals A G composições compreendendo um inibidor de crac e um corticosteroide e métodos de uso dos mesmos

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
IL144826A0 (en) 1999-02-10 2002-06-30 Welfide Corp Amide compounds and pharmaceutical compositions containing the same
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
US8084467B2 (en) 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
WO2003035602A1 (en) 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
EP1451160B1 (en) 2001-11-01 2010-01-13 Icagen, Inc. Pyrazole-amides for use in the treatment of pain
TWI376370B (en) 2003-07-23 2012-11-11 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
AU2004265299B2 (en) 2003-08-07 2008-05-01 Merck & Co., Inc. Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
AT7990U1 (de) 2004-12-22 2005-12-15 Gottfried Steiner Ingenieurbue Spritzgussform
EP1844020B1 (en) 2005-01-10 2017-09-06 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptor ligands
AU2006261841B8 (en) 2005-06-27 2012-12-06 Exelixis Patent Company Llc Pyrazole based LXR modulators
WO2007024744A2 (en) 2005-08-21 2007-03-01 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptor ligands
WO2007043400A1 (ja) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
WO2007087441A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
US8455658B2 (en) 2006-01-25 2013-06-04 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
US8642597B2 (en) 2007-08-27 2014-02-04 Basf Se Pyrazole compounds for controlling invertebrate pests
WO2009052062A1 (en) 2007-10-17 2009-04-23 Sanofi-Aventis Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
US8389567B2 (en) * 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2711644A1 (en) 2008-01-07 2009-07-16 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
GB0813042D0 (en) 2008-07-16 2008-08-20 Syngenta Participations Ag Insecticidal compounds
EP2350084B1 (en) 2008-10-17 2015-06-24 Boehringer Ingelheim International GmbH Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
AR076373A1 (es) 2009-04-24 2011-06-08 Glaxo Group Ltd N-pirazolil carboxamidas como inhibidores de canales de calcio
US8377970B2 (en) * 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
KR20140051835A (ko) 2011-02-09 2014-05-02 신젠타 파티서페이션즈 아게 살곤충 화합물
EP2702055A1 (en) 2011-04-11 2014-03-05 Nerviano Medical Sciences S.r.l. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
EP2532661A1 (en) 2011-06-10 2012-12-12 Syngenta Participations AG Novel insecticides

Also Published As

Publication number Publication date
AU2014204977A1 (en) 2015-08-20
WO2014108336A8 (en) 2015-07-16
IL239789A0 (en) 2015-08-31
ZA201505697B (en) 2017-01-25
CA2897560A1 (en) 2014-07-17
BR112015016394A2 (pt) 2017-07-11
JP2016504397A (ja) 2016-02-12
CN104884058A (zh) 2015-09-02
US20140194452A1 (en) 2014-07-10
EA201500737A1 (ru) 2016-04-29
WO2014108336A1 (en) 2014-07-17
HK1216301A1 (zh) 2016-11-04
MX2015008912A (es) 2015-10-22
EP2943197A1 (en) 2015-11-18
KR20150103752A (ko) 2015-09-11
US9078899B2 (en) 2015-07-14

Similar Documents

Publication Publication Date Title
AR097325A1 (es) Pirroles anillados
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR103561A1 (es) Fenilpiridinas herbicidas
AR102492A1 (es) Cromanos sustituidos y métodos para su uso
CY1124076T1 (el) Ημιθειικο αλας του 5,10-μεθυλενο-(6r)-τετραϋδροφυλλικου οξεος
CR20180185A (es) Métodos y composiciones para el tratamiento de estados de enfermedad asociados con respuestas inflamatorias anormales
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
EA201791151A1 (ru) Новая кристаллическая форма производного бензимидазола и способ ее получения
MX385158B (es) Derivados indol para uso en medicina.
AR094412A1 (es) Carboxamidas basadas en pirazolilo i
AR091023A1 (es) Inhibidores del nampt
UY36121A (es) ?pirazolopiridinas y pirazolopirimidinas?.
AR105075A1 (es) Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
EA201691512A1 (ru) Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2
PE20151860A1 (es) Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhidores de la phd
AR088535A1 (es) Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1)
AR098776A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
AR100073A1 (es) Sulfonas heterocíclicas sustituidas con heteroarilos
PE20170303A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
AR094159A1 (es) Compuesto de [1,2,4]triazol e imidazol sustituidos
ZA201607097B (en) Liquid formulation comprising gm-csf neutralizing compound
AR091455A1 (es) Derivados 1,3-dihidro-2h-benzimidazol-2-ona sustituidos con heterociclos como agentes antivirales para el virus sincicial respiratorio
EA202092464A1 (ru) Способы получения стабильных композиций на основе белков
UY35535A (es) ?Derivados de fenil sulfonamidas?.

Legal Events

Date Code Title Description
FB Suspension of granting procedure